Also, treatment of KLF5 knockdown and control prostate cancer cells with MG132, a proteasome inhibitor, for different times did not show a significant difference in the BECN1 protein levels between the two groups (Figure S1A-S1B). This evidence concerns the gene BECN1 and prostate cancer.